Pfizer delivered a stronger-than-expected second quarter as continued demand for its blood thinner Eliquis and contributions from recently acquired medicines helped offset the ongoing decline in COVID-related revenue. The pharmaceutical giant also announced another $2.5 billion in planned cost reductions as it continues reshaping the business for growth beyond its legacy products.
The latest results come at an important point for Pfizer. The company has spent the past several years working through the sharp decline in demand for its COVID-19 products while attempting to rebuild investor confidence through acquisitions, pipeline investments and operational savings. Pfizer now expects total net savings from its cost-cutting programs to reach approximately $9.7 billion through 2029.
The performance provides some reassurance that the pharmaceutical company’s broader portfolio can absorb the decline in pandemic-related products. However, investors remain focused on whether Pfizer can turn its restructuring program and recent acquisitions into sustainable growth, particularly as several major products approach patent expirations.
Eliquis and acquisitions provide support as Pfizer cuts costs
Eliquis remained an important contributor to Pfizer’s quarterly performance, reflecting continued demand for the anticoagulant. The drug, which Pfizer commercializes with Bristol Myers Squibb, has become one of the company’s most important established products and continues to provide significant revenue as Pfizer works to transition toward newer medicines.
The company is also benefiting from medicines obtained through recent acquisitions, giving its portfolio additional sources of revenue at a time when COVID products are no longer generating the exceptional sales seen during the pandemic.
Pfizer’s management is simultaneously pushing ahead with a broad cost-reduction program. The additional $2.5 billion in savings announced with the results brings the company’s expected cumulative net savings through 2029 to roughly $9.7 billion.
Chief Executive Officer Albert Bourla said the restructuring has already reduced administrative, sales and marketing expenses by about 3% during the first half of the year. At the same time, research and development spending increased 12% year over year.
That combination is central to Pfizer’s strategy. Rather than treating cost reductions simply as a way to protect margins, the company is attempting to redirect some of the savings toward research and development and future growth opportunities.
Bourla said the company is generating efficiencies particularly across support functions such as finance, legal and human resources while continuing to invest in R&D. The approach reflects a broader effort across large pharmaceutical companies to reduce operating complexity without weakening investment in new medicines.
Pfizer expects the current restructuring period to eventually give way to faster growth. Management has indicated that the company expects growth to accelerate again after 2028, although investors are likely to look for evidence of that recovery well before then.
The company’s shares rose 2.3% following the results, suggesting that the quarterly performance provided some relief to investors who have been closely monitoring Pfizer’s ability to stabilize its business.
Still, the longer-term picture remains complicated. Pfizer faces upcoming patent expirations that could put pressure on established revenue streams, making the development and commercialization of replacement products increasingly important.
Obesity and oncology acquisitions become central to Pfizer’s next phase
Pfizer’s $10 billion acquisition of Metsera is one of the most closely watched pieces of its growth strategy. The deal gives Pfizer exposure to the rapidly expanding obesity medicines market, which analysts expect could reach approximately $150 billion in annual value over the next decade.
The opportunity is significant, but so is the competitive pressure. The obesity market is dominated by rapidly advancing treatments from major drugmakers, creating a high bar for new entrants. Pfizer will need to demonstrate that Metsera’s portfolio can provide meaningful clinical or commercial differentiation as the company attempts to establish a durable position.
The acquisition also illustrates a broader change in Pfizer’s approach to dealmaking. Bourla said the company has already made major M&A decisions in areas including obesity and cancer. Going forward, Pfizer expects to focus more heavily on smaller bolt-on acquisitions across different therapeutic categories.
The company estimates it has approximately $6 billion of remaining capacity for deals, giving management room to add targeted assets without pursuing another transaction on the scale of its largest recent acquisitions.
Cancer is another important area for Pfizer as it works to build a portfolio capable of supporting long-term growth. The company has increasingly used acquisitions to strengthen its presence in oncology and other high-value therapeutic markets, rather than relying entirely on internal research.
At the same time, Pfizer is preparing for a leadership transition in its finance organization. Chief Financial Officer Dave Denton is scheduled to leave later this month, and the company is searching for his successor. The incoming CFO will inherit responsibility for balancing investment, cost management, acquisitions and shareholder returns during a particularly important period for the company.
Bourla also indicated that Pfizer intends to continue increasing its dividend after addressing several upcoming patent expirations. That commitment will be closely watched alongside the company’s efforts to restore organic growth.
For investors, the second-quarter earnings beat therefore represents only part of the story. The immediate results demonstrate resilience across Pfizer’s portfolio, but the bigger test is whether the company can translate that stability into sustained expansion.
RBC Capital analyst Trung Huynh said Pfizer needs to deliver important catalysts through 2026 if it wants the market to view the company as a growth business again rather than primarily as a restructuring story.
That distinction captures the challenge facing Pfizer. Cost reductions can improve efficiency, while acquisitions can provide new products and market access. Neither, however, guarantees long-term growth.
The company’s next phase will depend on its investments in obesity, cancer and other therapeutic areas can replace declining legacy revenue and create a stronger product base before the impact of future patent losses becomes more pronounced. For now, Eliquis, acquired medicines and disciplined spending are giving Pfizer additional time to make that transition.
